Ipsen Posts 10.9% Sales Growth in 2025, Eyes Double-Digit Expansion in 2026
Event summary
- Ipsen reported 10.9% constant currency sales growth in 2025, with Rare Disease segment surging 102.5%.
- Core operating income rose 16.7% to €1.29 billion, with a 35.2% margin.
- 2026 guidance projects over 13% sales growth, driven by Somatuline® and pipeline acceleration.
- Acquired ImCheck Therapeutics to bolster immuno-oncology portfolio.
- Five major regulatory and clinical milestones expected in 2026.
The big picture
Ipsen's strong 2025 performance reflects successful execution across oncology, rare disease, and neuroscience. The company's aggressive 2026 guidance hinges on pipeline momentum and Somatuline® market dynamics. In a competitive biopharma landscape, Ipsen's ability to sustain double-digit growth will depend on regulatory approvals and external innovation success.
What we're watching
- Pipeline Execution
- Whether Ipsen can deliver on five key regulatory and clinical milestones in 2026, including tovorafenib approval and IPN10200 data.
- Generic Competition
- The duration of Somatuline® sales growth due to generic lanreotide production challenges.
- Innovation Strategy
- The integration and impact of ImCheck Therapeutics' assets on Ipsen's immuno-oncology pipeline.
Related topics